Clozapine Titration for People in Early Psychosis
Authors:
- 1 June 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 38 (3) , 234-238
Abstract
Purpose/Background The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to repeated trials of less effective medications. Current clozapine dosing recommendations are based on people further in the course of their illness and thus reflect different responsiveness and sensitivities to antipsychotic medication. As such, there is a need for evidence-based guidelines for titration and dosing of clozapine among people in early psychosis. Methods/Procedures We performed a chart review of 14 people treated with clozapine within our early psychosis team. Data regarding dose titration, response, time to discontinuation, symptom severity, weight gain, and other adverse effects were gathered at clozapine initiation, 3 months, and last available visit on clozapine. Findings/Results People treated with slow titration within their first year of psychosis onset achieved sustained response at very low maintenance doses (mean dose = 81 mg/d, mean duration of treatment = 200 weeks) compared with slow titration with longer duration of illness (mean dose = 350 mg/d, mean duration of treatment = 68 weeks) or standard dose titration in early psychosis (mean dose = 112 mg/d, mean duration of treatment = 38 weeks). The most common adverse effects in all groups were weight gain and sedation, with the groups requiring higher mean doses reporting a broader range of adverse effects. There was no apparent difference in the clinical global impression for severity or improvement between the slow titration and standard titration groups in people with early psychosis. These observations are synthesized into a proposed treatment guideline for use of clozapine among people in early psychosis. Implications/Conclusions We describe development of a slow titration approach to initiating clozapine among people in early psychosis. This approach resulted in clinical response at remarkably low maintenance doses of clozapine among people within their first year of illness, but not in those with longer duration of symptoms. Slow titration also led to good tolerability and acceptance of clozapine treatment for some patients.Keywords
This publication has 13 references indexed in Scilit:
- Glasgow Antipsychotic Side-effects Scale for Clozapine — Development and validation of a clozapine-specific side-effects scaleSchizophrenia Research, 2015
- Results of phase 3 of the CATIE schizophrenia trialSchizophrenia Research, 2009
- Early Use of Clozapine for Poorly Responding First-Episode PsychosisJournal of Clinical Psychopharmacology, 2007
- Why Not Clozapine?Clinical Schizophrenia & Related Psychoses, 2007
- Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic TreatmentAmerican Journal of Psychiatry, 2006
- International clinical practice guidelines for early psychosisThe British Journal of Psychiatry, 2005
- The Texas Medication Algorithm Project Antipsychotic Algorithm for SchizophreniaThe Journal of Clinical Psychiatry, 2004
- Clozapine as a First Treatment for SchizophreniaAmerican Journal of Psychiatry, 2003
- Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs ChlorpromazineNeuropsychopharmacology, 2003
- Clozapine Treatment for Suicidality in SchizophreniaInternational Suicide Prevention Trial (InterSePT)Archives of General Psychiatry, 2003